High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.

AUTOR(ES)

Jann, S

RESUMO

Two patients were treated with treatment-resistant polymyositis with intravenous immunoglobulin over four days at a dose of 0.4 g/kg/day. Clinical recovery followed within two months. Serum creatine kinase (CK) activity decreased to normal, and a clear improvement in muscle strength was observed. One patient showed neither clinical relapses nor increase in serum CK activity after 20 months. The other showed a mild increase in serum CK activity after 24 months and was successfully retreated with intravenous immunoglobulin. There were no significant adverse side effects.

Documentos Relacionados

• High-dose immunoglobulin in Felty's syndrome.
• High-dose intravenous methylprednisolone in rheumatoid arthritis.
• Pharmacokinetic Profiles of High-Dose Intravenous Ciprofloxacin in Severe Sepsis
• High-Dose Intravenous Ribavirin Therapy for Subacute Sclerosing Panencephalitis
• Limited effects of high‐dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies